UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 24, 2017
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-53500 | 87-0622284 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 2017 W Peoria Avenue, Phoenix, AZ 85029 |
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01. | Other Events |
On May 24, 2017, Creative Medical Technology Holdings, Inc. (the “Company”) issued a press release announcing the filing of a patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming immune cells of the stroke victim.
The press release, furnished as Exhibit 99.1 to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently available to the registrant’s management and are current only as of the date made. Actual results could also differ materially from those anticipated as a result of a number of factors, including, but not limited to, those discussed in the registrant’s Annual Report on Form 10-K for the year ended December 31, 2016, and subsequent reports filed by the Company with the Commission. For those reasons, undue reliance should not be placed on any forward-looking statement. The Company assumes no duty or obligation to update or revise any forward-looking statement, although it may do so from time to time as management believes is warranted or as may be required by applicable securities law. Any such updates or revisions may be made by the registrant by filing reports with the Commission, through the issuance of press releases or by other methods of public disclosure.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated May 24, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Creative Medical Technology Holdings, Inc. | |||
| Date: May 24, 2017 | By: | /s/ Timothy Warbington | |
| Timothy Warbington, Chief Executive Officer | |||
Exhibit 99.1
Creative Medical Technology Holdings, Inc. Files Patent on AmnioStem™
Mediated Immune Reprogramming for Stroke
Company Discovers Novel Method of Suppressing Inflammation
Using Combination Autologous Allogeneic System
May 24, 2017 – Phoenix, AZ and San Diego, CA, Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the “Company”) announced today the filing of a patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming immune cells of the stroke victim.
The patent application teaches ways of using the Company’s patented AmnioStem™ allogeneic stem cell to ‘educate’ immune cells from stroke patients so as to reduce inflammation associated with stroke. By reducing inflammation, the Company hopes to develop novel means of increasing efficacy of therapeutic agents in stroke patients.
“We are highly enthusiastic with our current data, which seems to suggest that AmnioStem™ cells are not only capable of inducing regeneration of injured brains, but also can be used to ‘reprogram’ immune system cells of patients in order to reduce inflammation that occurs subsequent to stroke.” Said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “Working together with immunologists, neurologists, and stem cell experts, we are fortunate to have a team that can attack the problem of stroke in a multidisciplinary manner.”
It is known that the immune system contributes to the deterioration of brain functions after a stroke. For example, studies in the mouse model of stroke have shown that if certain immune cells are depleted, the neurological impact of a stroke is diminished.1 It is also known that part of the therapeutic activities of stem cells in a stroke are mediated by alterations of the immune system.2
“We are confident that the novel findings presented in the patent application will pave the way for using AmnioStem™ treated patient immune cells as a means of suppressing pathological responses, which is applicable not only to stroke but to a wide variety of neuroinflammatory conditions including multiple sclerosis and traumatic brain injury.” Said Thomas lchim, Ph.D., Chief Scientific Officer of Creative Medical Technology Holdings.
1 Belinga et al. Splenectomy following MCAO inhibits the TLR4-NF-KB signaling pathway and protects the brain from neurodegeneration in rats. J Neuroimmunol. 2016 Apr 15; 293:105-13
https://www.ncbi.nlm.nih.gov/pubmed/27049570
2 Cheng et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation. Brain Res. 2015 Jan 12;1594:293-304.
https://www .ncbi.nlm.nih.gov/pubmed/?term=25449888
About US
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company with two focus areas: 1) Personalized stem cell procedures for sexual dysfunction and infertility; and 2) Universal, off-the-shelf amniotic fluid-based stem cells that possess superior healing potential without negative medical or ethical issues.
Since 2011, through our own research and collaborations with leading academic institutions, we have developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction and are performing ground-breaking research with our amniotic fluid-based stem cell.
For additional information visit: www.CREATIVEMEDICALTECHNOLOGY.com
Forward-Looking Statements
This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “aim”, “will likely result”, “believe”, “expect”, “anticipate”, “estimate”, “intend”, ’‘plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, ’‘project”, “should” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Investor Relations
Andrew Barwicki
516-662-9461/andrew@barwicki.com